FierceBiotech· @FierceBiotech · X·· 13 天前精选AI 评分58
AI 导读
赛诺菲在启动I期试验仅两个月后,终止了从Nurix授权引进的STAT6降解剂项目。该决定发生在新任CEO主导的管线调整背景下,Fierce Biotech给出了相关报道链接。
推荐理由
赛诺菲在启动I期试验两个月后即终止从Nurix引进的STAT6降解剂,可观察新任CEO管线调整的取舍节奏。
正文
Just two months after launching a phase 1 trial, Sanofi is pulling the plug on a STAT6 degrader licensed from Nurix. The decision comes amid a broader pipeline shake-up under Sanofi's new CEO. https://www.fiercebiotech.com/biotech/sanofi-scraps-stat6-degrader-nurix-just-2-months-after-entering-clinic
来源:FierceBiotech · x.com